Virotherapy clinical trials for regional disease: In situ immune modulation using recombinant poxvirus vectors (original) (raw)
Lattime EC, Gerson SL . Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation 2nd ed San Diego: Academic Press 2002 534 Google Scholar
Thomas L . In: Lawrence HS, ed Cellular and Humoral Aspects of the Hypersensitive States New York: Hoeber-Harper 1959 529–532 Google Scholar
Bodurtha AJ, Berkelhammer J, Kim YH, Laucius JF, Mastrangelo MJ . A clinical, histologic, and immunologic study of a case of metastatic malignant melanoma undergoing spontaneous remission Cancer 1976 37: 735–742 ArticleCASPubMed Google Scholar
Spontaneous Remission: An Annotated Bibliography Sausalito, CA: Institute of Noetic Sciences 1993 1–710
Ostrand-Rosenberg S, Clements VK, Dissanayake S, Gilbert M, Pulaski BA, Qi L . Immunologic targets for the gene therapy of cancer In: Lattime EC, Gerson SL, eds Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation 2nd ed San Diego: Academic Press 2002 128–144 Google Scholar
Bornstein RS, Mastrangelo MJ, Sulit H et al. Immunotherapy of melanoma with intralesional BCG Natl Cancer Inst Monogr 1973 39: 213–220 CASPubMed Google Scholar
Laucius JF, Bodurtha AJ, Mastrangelo MJ, Creech RH . Bacillus Calmette–Guerin in the treatment of neoplastic disease J Reticuloendothel Soc 1974 16: 347–373 CASPubMed Google Scholar
Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM . Bacillus Calmette–Guerin immunotherapy of superficial bladder cancer J Urol 1980 124: 38–42 ArticleCASPubMed Google Scholar
Mastrangelo MJ, Maguire HCJ, Lattime EC, Berd D . Whole cell vaccines In: DaVita VT, Hellman S, Rosenberg SA, eds Biological Therapy of Cancer 2nd ed Philadelphia: Lippincott 1995 648–658 Google Scholar
Mastrangelo MJ, Sato T, Lattime EC, Maguire HC Jr, Berd D . Cellular vaccine therapies for cancer In: Foon KA, Muss HB, eds Biological and Hormonal Therapies of Cancer Boston: Kluwer Academic Publishing 1998 35–50 Chapter Google Scholar
Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B . Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with MAGE-1 peptide loaded antigen presenting cell–based vaccine Cancer Res 1996 56: 2479–2483 CASPubMed Google Scholar
Schlom J, Tsang K-Y, Kantor J et al. Strategies in the development of recombinant vaccines for colon cancer Semin Oncol 1999 26: 672–682 CASPubMed Google Scholar
Marshall JL, Hoyer RJ, Toomey MA et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses J Clin Oncol 2000 18: 3964–3973 ArticleCASPubMed Google Scholar
Horig H, Lee DS, Conkright W et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule Cancer Immunol Immunother 2000 49: 504–514 ArticleCASPubMed Google Scholar
Eder JP, Kantoff PW, Roper K et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer Clin Cancer Res 2000 6: 1632–1638 CASPubMed Google Scholar
Sanda MG, Smith DC, Charles LG et al. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer Urology 1999 53: 260–266 ArticleCASPubMed Google Scholar
Fearon ER, Pardoll DM, Itaya T et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response Cell 1990 60: 397–403 ArticleCASPubMed Google Scholar
Asher AL, Mulé JJ, Kasid A et al. Murine tumor cells transduced with the gene for tumor necrosis factor-α: evidence for paracrine immune effects of tumor necrosis factor against tumors J Immunol 1991 146: 3227–3234 CASPubMed Google Scholar
Watanabe Y, Kuribayashi K, Miyatake J et al. Exogenous expression of mouse interferon-gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity Proc Natl Acad Sci USA 1989 86: 9456–9460 ArticleCASPubMedPubMed Central Google Scholar
Tepper RI, Pattengale PK, Leder P . Murine interleukin-4 displays potent anti-tumor activity in vivoCell 1989 57: 503–512 ArticleCASPubMed Google Scholar
Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E . Regression of bladder tumors in mice treated with interleukin 2 gene–modified tumor cells J Exp Med 1993 177: 1127–1134 ArticleCASPubMed Google Scholar
Saito S, Bannerji R, Gansbacher B et al. Immunotherapy of bladder cancer with cytokine gene–modified tumor vaccines Cancer Res 1994 54: 3516–3520 CASPubMed Google Scholar
Dranoff G, Jaffee E, Lazenby A . Vaccination with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity Proc Natl Acad Sci USA 1993 90: 3539–3543 ArticleCASPubMedPubMed Central Google Scholar
Simons JW, Mikhak B, Chang JF et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte–macrophage colony-stimulating factor using ex vivo gene transfer Cancer Res 1999 59: 5160–5168 CASPubMed Google Scholar
Simons JW, Jaffee EM, Weber CE et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte–macrophage colony-stimulating factor gene transfer Cancer Res 1997 57: 1537–1546 CASPubMedPubMed Central Google Scholar
Nelson WG, Simons JW, Mikhak B et al. Cancer cells engineered to secrete granulocyte–macrophage colony- stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies Cancer Chemother Pharmacol 2000 46: S67–S72 ArticleCASPubMed Google Scholar
Perussia B, Chan SH, D'Andrea A et al. Natural killer cell stimulatory factor or interleukin-12 has differential effects on the proliferation of TCRαβ+, TCRτδ+ T lymphocytes and NK cells J Immunol 1992 149: 3495–3502 CASPubMed Google Scholar
Golumbek PT, Lazenby AJ, Levitsky HI et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4 Science 1991 254: 713–716 ArticleCASPubMed Google Scholar
Kusumoto M, Umeda S, Ikubo A et al. Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene Cancer Immunol Immunother 2001 50: 373–381 ArticleCASPubMed Google Scholar
Chang AE, Li Q, Bishop DK, Normolle DP, Redman BD, Nickoloff BJ . Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte–macrophage colony-stimulating factor Hum Gene Ther 2000 11: 839–850 ArticleCASPubMed Google Scholar
Soiffer R, Lynch T, Mihm M et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte–macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma Proc Natl Acad Sci USA 1998 95: 13141–13146 ArticleCASPubMedPubMed Central Google Scholar
Tahara H, Zeh HJ, Storkus WJ et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in-vivoCancer Res 1994 54: 182–189 CASPubMed Google Scholar
Lotze MT, Rubin JT, Carty S et al. Gene therapy of cancer: a pilot study of IL-4-gene–modified fibroblasts admixed with autologous tumor to elicit an immune response Hum Gene Ther 1994 5: 41–55 ArticleCASPubMed Google Scholar
Kang WK, Park C, Yoon HL et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study Hum Gene Ther 2001 12: 671–684 ArticleCASPubMed Google Scholar
Lee SS, Eisenlohr LC, McCue PA, Mastrangelo MJ, Lattime EC . Intravesical gene therapy: vaccinia virus recombinants transfect murine bladder tumors and urothelium Proc Am Assoc Cancer Res 1993 34: 337 Google Scholar
Lee SS, Eisenlohr LC, McCue PA, Mastrangelo MJ, Lattime EC . Intravesical gene therapy: in-vivo gene transfer using vaccinia vectors Cancer Res 1994 54: 3325–3328 CASPubMed Google Scholar
Lattime EC, Maguire HCJ, McCue PA et al. Infection of human melanoma cells by intratumoral vaccinia J Invest Dermatol 1994 102: 568 Google Scholar
Mastrangelo MJ, Maguire HC Jr, McCue PA . A pilot study demonstrating the feasibility of using intratumoral vaccinia injections as a vector for gene transfer Vaccine Res 1995 4: 55–69 Google Scholar
Gomella LG, Mastrangelo MJ, Eisenlohr LC, McCue PA, Lee SS, Lattime EC . Localized gene therapy for prostate cancer: strategies for intraprostatic cytokine gene transfection using vaccinia virus vectors J Urol 1995 153: 308A Article Google Scholar
Lattime E, Eisenlohr L, Gomella L, Mastrangelo M . The use of vaccinia virus vectors for immunotherapy via in-situ tumor transfection In: Lattime E, Gerson S, eds Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation San Diego: Academic Press 1999 125–137 Google Scholar
Lee SS, Eisenlohr LC, McCue PA, Mastrangelo MJ, Fink E, Lattime EC . In-vivo gene therapy of murine tumors using recombinant vaccinia virus encoding GM-CSF Proc Am Assoc Cancer Res 1995 36: 248 Google Scholar
Lee SS, Eisenlohr LC, McCue PA, Mastrangelo MJ, Lattime EC . Vaccinia virus vector mediated cytokine gene transfer for in vivo tumor immunotherapy Proc Am Assoc Cancer Res 1994 35: 514 Google Scholar
Ramshaw IA, Ramsay AJ, Karupiah G, Rolph MS, Mahalingam S, Ruby JC . Cytokines and immunity to viral infections Immunol Rev 1997 159: 119–135 ArticleCASPubMed Google Scholar
Lattime EC, Maguire HCJ, McCue PA et al. Gene therapy using vaccinia vectors: repeated intratumoral injections result in tumor infection in the presence of anti-vaccinia immunity Proc Am Soc Clin Oncol 1994 13: 397 Google Scholar
Ostrand-Rosenberg S, Pulaski BA, Armstrong TD, Clements VK . Immunotherapy of established tumor with MHC class II and B7.1 cell–based tumor vaccines Adv Exp Med Biol 1998 451: 259–264 ArticleCASPubMed Google Scholar
Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC . Intratumoral recombinant GM-CSF–encoding virus as gene therapy in patients with cutaneous melanoma Cancer Gene Ther 1999 6: 409–422 ArticleCASPubMed Google Scholar
Gomella LG, Mastrangelo MJ, McCue PA, Maguire HC, Mulholland SG, Lattime EC . Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer J Urol 2001 166: 1291–1295 ArticleCASPubMed Google Scholar
Mukherjee S, Haenel T, Himbeck R et al. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation Cancer Gene Ther 2000 7: 663–670 ArticleCASPubMed Google Scholar
Robinson BW, Mukherjee SA, Davidson A et al. Cytokine gene therapy or infusion as treatment for solid human cancer J Immunother 1998 21: 211–217 ArticleCASPubMed Google Scholar
Kaufman HL, Conkright W, Divito J Jr et al. A phase I trial of intra lesional RV-B7.1 vaccine in the treatment of malignant melanoma Hum Gene Ther 2000 11: 1065–1082 ArticleCASPubMed Google Scholar
Kaufman HL, DeRaffele G, Divito J et al. A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma Hum Gene Ther 2001 12: 1459–1480 ArticleCASPubMed Google Scholar